Back to top
more

ImmunoGen, Inc. (IMGN)

(Delayed Data from NSDQ)

$2.88 USD

2.88
5,883,771

+0.38 (15.20%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.93 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

New Strong Buy Stocks for October 20th

OSCR, IMGN, AFRM, ACVA and SOLO have been added to the Zacks Rank #1 (Strong Buy) List on October 20, 2023.

New Strong Buy Stocks for October 18th

MRO, APA, IMGN, RAIL and MFA have been added to the Zacks Rank #1 (Strong Buy) List on October 18, 2023.

Tirthankar Chakraborty headshot

3 Solid Stocks to Buy for Superb Earnings Acceleration

Invest in stocks such as Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN) and Inari Medical (NARI) for solid earnings acceleration.

Tirthankar Chakraborty headshot

4 Stocks That Exhibit Solid Earnings Acceleration

Invest in stocks like Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN), Inari Medical (NARI) and Kyndryl Holdings (KD) for superb earnings acceleration.

Wall Street Analysts Think ImmunoGen (IMGN) Could Surge 49.11%: Read This Before Placing a Bet

The mean of analysts' price targets for ImmunoGen (IMGN) points to a 49.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Why Is Catalyst (CPRX) Down 14% Since Last Earnings Report?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Nektar (NKTR) Down 37.1% Since Last Earnings Report?

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Deciphera (DCPH) Q2 Earnings Beat, Qinlock Drives Revenues

Deciphera (DCPH) reports narrower-than-expected loss for the second quarter of 2023. Qinlock drives year-over-year sales.

Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Beat

Emergent (EBS) reports wider-than-expected second-quarter loss. The company lowered its 2023 guidance for some products and services.

Amicus (FOLD) Misses on Q2 Earnings, Raises Revenue Guidance

Amicus (FOLD) incurs wider-than-expected loss in the second quarter. Fabry disease drug Galafold reports encouraging revenues and the company raises its 2023 guidance for the same.

Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss

Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year.

Axsome (AXSM) Q2 Earnings Beat, Stock Dips on Pipeline Updates

Axsome (AXSM) incurs a narrower-than-expected loss in the second quarter. The company provides updates on its central nervous system candidates.

Intellia (NTLA) Misses on Q2 Earnings, Gives Pipeline Update

Intellia's (NTLA) second-quarter earnings miss estimates. The company provides an update on its gene-editing pipeline.

Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line

Agios (AGIO) reports narrower-than-expected loss in the second quarter of 2023. The revenues are in line with the Zacks Consensus Estimate.

Corcept (CORT) Beats on Q2 Earnings, Ups '23 Sales View

Corcept's (CORT) second-quarter earnings and revenues beat estimates. The company gives updates on its pipelines and raises revenue guidance for 2023, reflecting strong performance of Korlym.

Amarin (AMRN) Q2 Earnings and Revenues Surpass Estimates

Amarin's (AMRN) second-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.

Repligen (RGEN) Beats on Q2 Earnings, Lowers '23 Guidance

Repligen's (RGEN) second-quarter earnings and revenues beat their respective Zacks Consensus Estimate. Chromatography and process analytics businesses are the key growth drivers in the quarter.

Esperion (ESPR) Q2 Earnings Top, Stock Up on Strong Revenues

Esperion's (ESPR) second-quarter earnings and revenues beat estimates. The stock surged 7.64% on Tuesday.

ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat

ImmunoGen's (IMGN) Q2 earnings show an encouraging adoption of the sole-marketed drug Elahere. The company, however, did not issue any product sales guidance for Elahere for 2023.

Best Momentum Stocks to Buy for August 1st

UAL, BJRI and IMGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 1, 2023.

ImmunoGen (IMGN) Reports Q2 Loss, Tops Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 87.50% and 94.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ImmunoGen (IMGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

ImmunoGen (IMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?

Here is how ANI Pharmaceuticals (ANIP) and ImmunoGen (IMGN) have performed compared to their sector so far this year.

ImmunoGen (IMGN) Crossed Above the 20-Day Moving Average: What That Means for Investors

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?